There is a growing demand for the development of high-throughput assays to evaluate channel blockers under different states, as this likely provides highly-desired selectivity for pathologically over-activated Cav1.3 channels. However, current screening methodologies for this channel have significant limitations.
Molecular Devices have put together an application note, in which they report a novel solution using optogenetic methods to control Vm via channelrhodopsin-2 (ChR2).
- Target-specific and non-invasive assay method via light application
- Flexible and reversible assay protocol
- Data quality matching electrophysiology and potassium stimulus
If you have any interest in learning more about Molecular Devices products – of any kind – please fill in the application form at this link (this shows you read about this on my website and links it back to me. You don’t have to do this, but it would be appreciated)